Department of Surgery, Zhongshan Hospital, Fudan University School of Medicine, Shanghai 200032, China.
IUBMB Life. 2012 Sep;64(9):775-82. doi: 10.1002/iub.1066. Epub 2012 Jul 18.
Pyruvate kinase type M2 (PKM2) has been reported to be involved in aerobic glycolysis and cell growth in various tumors. However, the expression pattern of PKM2 in colorectal cancer (CRC) and the correlation between PKM2 expression and CRC remains unclear. The aim of this study is to investigate PKM2 expression and its possible role in CRC. We found that expression of PKM2 was increased in CRC and the increased PKM2 expression was associated with later stage and lymph metastasis of the tumors. Knockdown of PKM2 suppressed the aerobic glycolysis and decreased lactate production of colon cancer RKO cells. Knockdown of PKM2 repressed proliferation and migration of the cells. Inhibition of PKM2 suppressed xenograft tumor growth of RKO cells in vivo. These results suggest that the expression of PKM2 plays a critical role in development of CRC, and it may provide a growth advantage for colon cancer cells. Thus, PKM2 might be a potential therapeutic target for CRC.
丙酮酸激酶 M2（PKM2）已被报道参与各种肿瘤中的有氧糖酵解和细胞生长。然而，PKM2 在结直肠癌（CRC）中的表达模式以及 PKM2 表达与 CRC 的相关性尚不清楚。本研究旨在探讨 PKM2 的表达及其在 CRC 中的可能作用。我们发现 PKM2 在 CRC 中表达增加，并且 PKM2 表达的增加与肿瘤的晚期和淋巴转移有关。PKM2 的敲低抑制了结肠癌 RKO 细胞的有氧糖酵解和乳酸生成。PKM2 的敲低抑制了细胞的增殖和迁移。PKM2 的抑制抑制了 RKO 细胞在体内的异种移植肿瘤生长。这些结果表明，PKM2 的表达在 CRC 的发展中起着关键作用，它可能为结肠癌细胞提供生长优势。因此，PKM2 可能是 CRC 的一个潜在治疗靶点。
